GreenLab Partners with Ginkgo Bioworks to Scale Up Production of Brazzein, a Novel Sweetener
To scale up its production of brazzein, GreenLab will leverage its proprietary technology to grow proteins inside corn kernels, optimizing its process with Ginkgo's Plant Trait Services, Protein Services, and Deployment Capabilities
The global sugar replacement market is growing due to increased consumer demand. Sugar substitutes can help manage obesity, but some artificial sweeteners have been linked to various health issues including heart disease. Novel sweeteners — like brazzein, which has a sweetness factor up to 2,000 times greater than sucrose — can be used as natural substitutes for sugar in products across the food and beverage industry.
GreenLab hopes to revolutionize the sweetener industry with brazzein. Its proprietary technology allows it to grow enzymes and other proteins inside of corn kernels. By producing proteins in a cultivated crop, GreenLab can readily scale production across acres of cornfields, with little additional up-front capital and infrastructure. After the protein of interest is extracted from the kernel with minimal waste, most of the corn used will then proceed along the existing value chain, including food, feed or fuel. Thanks to its proprietary technology, GreenLab currently has two transformative enzymes in commercial production, including manganese peroxidase and laccase, and has already successfully grown corn containing brazzein.
GreenLab is leveraging Ginkgo's capabilities to scale up its production of brazzein in three ways:
- One, using Ginkgo Plant Trait Services to improve GreenLab's expression of brazzein in the corn kernel to achieve economically-competitive levels.
- Two, using Ginkgo Protein Services to express brazzein in a microbial chassis via precision fermentation.
- And three, using Ginkgo Deployment Capabilities to develop downstream processes to purify brazzein from both the corn kernel and fermentation broth.
By pursuing these pathways to brazzein production, GreenLab intends to be the preeminent supplier of brazzein to food and beverage companies, all while reducing market and technical risk.
Learn more about Ginkgo's Plant Trait Services, Protein Services, and Deployment Capabilities.
About
About GreenLab
GreenLab's mission is to green industry with next-generation plant biotechnology. Our platform transforms a cornfield into the factory of the future. We deliver on biotech's promise of next-generation proteins, end-to-end sustainability and unlimited scalability. GreenLab currently has two patented proteins growing in corn that are already in commercial production and is seeking partners who need to improve the cost, scale or environmental footprint of their protein biomanufacturing. Learn more at www.greenlab.com, or follow us on X as @GreenLabMfg or on LinkedIn.
Forward-Looking Statements of
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) the outcome of any pending or potential legal proceedings against Ginkgo, (vii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (viii) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (ix) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the
GINKGO BIOWORKS INVESTOR CONTACT:
investors@ginkgobioworks.com
GINKGO BIOWORKS MEDIA CONTACT:
press@ginkgobioworks.com
GREENLAB CONTACT:
SLallo@greenlab.com
401-465-5418
View original content to download multimedia:https://www.prnewswire.com/news-releases/greenlab-partners-with-ginkgo-bioworks-to-scale-up-production-of-brazzein-a-novel-sweetener-302137387.html
SOURCE